Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 5 | 2025 | 23 | 1.300 |
Why?
|
| Humans | 40 | 2025 | 4931 | 0.880 |
Why?
|
| African Americans | 8 | 2016 | 256 | 0.850 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 34 | 0.820 |
Why?
|
| Neoplasms | 5 | 2015 | 66 | 0.800 |
Why?
|
| Community Health Services | 4 | 2017 | 25 | 0.720 |
Why?
|
| Female | 26 | 2025 | 2964 | 0.690 |
Why?
|
| Poverty | 3 | 2016 | 53 | 0.670 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2020 | 2 | 0.620 |
Why?
|
| Middle Aged | 21 | 2025 | 1544 | 0.610 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 17 | 0.590 |
Why?
|
| Aged | 18 | 2025 | 1188 | 0.570 |
Why?
|
| Adult | 18 | 2025 | 1402 | 0.540 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 93 | 0.530 |
Why?
|
| Medically Uninsured | 2 | 2016 | 8 | 0.520 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 4 | 0.500 |
Why?
|
| Patient Navigation | 1 | 2016 | 4 | 0.500 |
Why?
|
| Health Status Disparities | 4 | 2015 | 69 | 0.470 |
Why?
|
| Albuminuria | 2 | 2012 | 24 | 0.460 |
Why?
|
| Male | 20 | 2020 | 2620 | 0.460 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 24 | 0.450 |
Why?
|
| Lymph Nodes | 1 | 2014 | 7 | 0.440 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 276 | 0.440 |
Why?
|
| Myometrium | 1 | 2014 | 10 | 0.440 |
Why?
|
| Urban Health Services | 1 | 2014 | 17 | 0.430 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 2 | 0.430 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 34 | 0.420 |
Why?
|
| Los Angeles | 9 | 2023 | 244 | 0.380 |
Why?
|
| Mass Screening | 1 | 2012 | 82 | 0.380 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 144 | 0.360 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 37 | 0.310 |
Why?
|
| Quality of Health Care | 1 | 2008 | 18 | 0.300 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 1 | 0.290 |
Why?
|
| Health Education | 1 | 2008 | 46 | 0.290 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 5 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 404 | 0.270 |
Why?
|
| Social Welfare | 1 | 2006 | 2 | 0.270 |
Why?
|
| Patient Care Management | 1 | 2006 | 3 | 0.270 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 5 | 0.270 |
Why?
|
| Prognosis | 5 | 2025 | 167 | 0.260 |
Why?
|
| Medicaid | 2 | 2007 | 14 | 0.250 |
Why?
|
| Peritoneum | 1 | 2025 | 4 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 154 | 0.240 |
Why?
|
| Immunotherapy | 1 | 2025 | 13 | 0.240 |
Why?
|
| DNA Mismatch Repair | 2 | 2025 | 4 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 23 | 0.230 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 170 | 0.230 |
Why?
|
| Health Services | 1 | 2004 | 11 | 0.230 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2024 | 1 | 0.230 |
Why?
|
| HIV Infections | 1 | 2006 | 167 | 0.220 |
Why?
|
| Clinical Medicine | 1 | 2004 | 2 | 0.220 |
Why?
|
| Health Services Research | 1 | 2004 | 24 | 0.220 |
Why?
|
| Adolescent | 7 | 2020 | 569 | 0.220 |
Why?
|
| Drinking Water | 1 | 2023 | 2 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 258 | 0.210 |
Why?
|
| United States | 6 | 2025 | 764 | 0.210 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2022 | 2 | 0.200 |
Why?
|
| Residence Characteristics | 2 | 2016 | 27 | 0.200 |
Why?
|
| Telemedicine | 1 | 2023 | 37 | 0.190 |
Why?
|
| Vaccines | 1 | 2022 | 8 | 0.190 |
Why?
|
| Insurance Coverage | 2 | 2016 | 12 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2019 | 162 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 37 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 1 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2020 | 4 | 0.170 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 5 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 4 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 33 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2019 | 24 | 0.160 |
Why?
|
| Young Adult | 6 | 2020 | 382 | 0.160 |
Why?
|
| Risk Factors | 5 | 2020 | 593 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 407 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2017 | 44 | 0.160 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 7 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 11 | 0.150 |
Why?
|
| Developing Countries | 2 | 2009 | 27 | 0.150 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 69 | 0.150 |
Why?
|
| Health Behavior | 3 | 2015 | 43 | 0.150 |
Why?
|
| Community Health Workers | 2 | 2008 | 13 | 0.140 |
Why?
|
| Perception | 2 | 2015 | 14 | 0.140 |
Why?
|
| Religion | 1 | 2017 | 1 | 0.140 |
Why?
|
| Allostasis | 1 | 2017 | 2 | 0.140 |
Why?
|
| Safety-net Providers | 1 | 2017 | 21 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 31 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 32 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 358 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2020 | 513 | 0.130 |
Why?
|
| Health Promotion | 1 | 2017 | 70 | 0.130 |
Why?
|
| Hypertension | 3 | 2019 | 123 | 0.130 |
Why?
|
| Chicago | 1 | 2016 | 4 | 0.130 |
Why?
|
| Health Status | 1 | 2016 | 61 | 0.120 |
Why?
|
| Research Subjects | 1 | 2015 | 6 | 0.120 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 13 | 0.120 |
Why?
|
| Trust | 1 | 2015 | 10 | 0.120 |
Why?
|
| Patient Selection | 1 | 2015 | 31 | 0.120 |
Why?
|
| Age Factors | 4 | 2020 | 152 | 0.120 |
Why?
|
| Feeding Behavior | 2 | 2012 | 28 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2016 | 135 | 0.110 |
Why?
|
| Registries | 3 | 2020 | 53 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 5 | 0.110 |
Why?
|
| SEER Program | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 14 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 39 | 0.110 |
Why?
|
| Delphi Technique | 1 | 2014 | 11 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 28 | 0.110 |
Why?
|
| Universities | 1 | 2014 | 18 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2014 | 17 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2014 | 41 | 0.100 |
Why?
|
| San Francisco | 2 | 2023 | 10 | 0.100 |
Why?
|
| Pandemics | 2 | 2024 | 65 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2025 | 229 | 0.100 |
Why?
|
| Internet | 1 | 2012 | 22 | 0.100 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 26 | 0.100 |
Why?
|
| Mortality, Premature | 1 | 2011 | 4 | 0.090 |
Why?
|
| Acute Kidney Injury | 2 | 2009 | 26 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 146 | 0.090 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 2 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 5 | 0.090 |
Why?
|
| Self Care | 1 | 2011 | 18 | 0.090 |
Why?
|
| Violence | 1 | 2011 | 42 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 49 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 1 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 30 | 0.080 |
Why?
|
| Health Surveys | 2 | 2008 | 55 | 0.080 |
Why?
|
| Zoonoses | 1 | 2009 | 2 | 0.080 |
Why?
|
| Leptospirosis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Snake Bites | 1 | 2009 | 7 | 0.080 |
Why?
|
| Case Management | 1 | 2008 | 4 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 39 | 0.070 |
Why?
|
| Food Supply | 1 | 2008 | 11 | 0.070 |
Why?
|
| Education | 1 | 2008 | 10 | 0.070 |
Why?
|
| Consensus | 1 | 2008 | 32 | 0.070 |
Why?
|
| Prevalence | 3 | 2019 | 184 | 0.070 |
Why?
|
| Public Health | 1 | 2008 | 31 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2015 | 127 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 5 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2007 | 23 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 48 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 16 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 1 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 12 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2025 | 8 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 11 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 30 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 1 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 1 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2024 | 8 | 0.060 |
Why?
|
| Risk-Taking | 2 | 2015 | 43 | 0.060 |
Why?
|
| Capital Financing | 1 | 2004 | 1 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 8 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 5 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Teaching | 1 | 2004 | 10 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 179 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 15 | 0.060 |
Why?
|
| Taxes | 1 | 2023 | 2 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 2 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 5 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 12 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 34 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 18 | 0.040 |
Why?
|
| Diet | 2 | 2012 | 95 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 14 | 0.040 |
Why?
|
| Endometrium | 1 | 2020 | 22 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 51 | 0.040 |
Why?
|
| Bolivia | 1 | 2020 | 1 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 4 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 6 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 24 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 13 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 132 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 177 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2019 | 27 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 137 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 7 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 7 | 0.040 |
Why?
|
| Child | 1 | 2020 | 336 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 123 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 32 | 0.030 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 4 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 17 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 69 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 402 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 73 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 146 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 8 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 3 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 3 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 12 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 17 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 92 | 0.030 |
Why?
|
| Animals | 2 | 2009 | 1369 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 84 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 224 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 15 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 30 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 33 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 53 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 37 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 1 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 1 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 3 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 29 | 0.020 |
Why?
|
| Integrative Medicine | 1 | 2011 | 2 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 21 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 14 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 41 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 13 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 16 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 2 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 50 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 202 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 120 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 3 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 4 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 4 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 14 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 6 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 58 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 45 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 69 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 8 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 10 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 59 | 0.020 |
Why?
|
| Biomarkers | 1 | 2008 | 160 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 8 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 67 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 47 | 0.020 |
Why?
|
| Social Class | 1 | 2007 | 34 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 45 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 41 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 77 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2006 | 113 | 0.010 |
Why?
|